{
  "id": 20303906,
  "title": "BioAge Labs at UBS conference: pivots BGE-102 toward eye disease",
  "url": "https://urgent.news/2026/11/16/bioage-labs-at-ubs-conference-pivots-bge-102-toward-eye-disease",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T17:25:31.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/bioage-labs-at-ubs-conference-pivots-bge102-toward-eye-disease-93CH-5030622"
  },
  "original_language": "en",
  "account": "At the UBS Global Biopharma Conference on November 16, 2026, BioAge Labs unveiled a revised strategy for its lead inflammation drug, BGE-102, and expanded its focus to obesity and aging biology. The company acknowledged a more challenging market for large cardiovascular outcomes trials following Novo Nordisk's failed ZEUS trial. BioAge is shifting BGE-102's focus from cardiovascular outcomes towards ophthalmology, particularly diabetic macular edema. Phase I data revealed up to 98% suppression of IL-1β, 86% reduction in CRP, and tolerability similar to placebo, with confirmed penetration to the brain and retina. The company holds approximately $350 million in cash, which is expected to support its programs through 2029. BioAge is advancing two APJ agonist programs, with an IND filing planned for late 2024. Despite a cautious stance on cardiovascular disease, the company remains optimistic about eye disease. BioAge's lead asset, BGE-102, is an oral NLRP3 inhibitor that targets upstream IL-1β and IL-18, which are associated with inflammation. The drug has demonstrated strong pharmacology and tolerability in multiple studies. BioAge's QUELL-CV study is a Phase II dose-ranging trial in obese individuals with elevated CRP and cardiovascular risk, while the QUELL-DME program is a Phase II proof-of-concept trial for diabetic macular edema. The oral route of BGE-102 could potentially benefit patients by reducing the need for injections and enabling more convenient management of the disease.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}